南宫NG·28(中国)相信品牌力量

Beijing, China – From May 12 to May 13, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Vascular and Endovascular Conference 2017 ("VEC 2017") in Beijing for academic exchange. The conference was hosted by China International Exchange and Promotion Association for Medical and Healthcare and Vascular Surgery Physicians Association of Beijing Medical Doctor Association. During the conference, domestic renowned vascular surgery specialists were gathered to share the latest advancement and development trend of China's vascular surgery industry.

During the session "TEVAR with Aortic Arch Involved," Professor Weiliang Jiang of the Second Affiliated Hospital of Harbin Medical University delivered a speech about "safety and efficient in one step - the clinical application of Castor™ Branched Aortic Stent-Graft System ("Castor™")" in which he introduced the clinical advantages and single-center trial results of Castor™. Professor Jiang said, Castor™ is the world's first unibody stent graft applied for branch vessel reconstruction, so that the aortic arch dissection/aneurysm can be treated by total endovascular method. The Second Affiliated Hospital of Harbin Medical University has completed 12 clinical cases using Castor™ in which nine patients with aortic dissection, two with thoracic aortic aneurysm and one with penetrating atherosclerotic aortic ulcer. All of the cases achieved successful outcome with zero occurrence rate of endoleak, showing superior result compared to Chimney technique and Hybrid technique. Professor Jiang said, branched aortic stent-graft system combined with other technique will be the primary means to tackle aortic arch and other branches.

Professor Qingsheng Lu of Changhai Hospital of the Second Military Medical University delivered a speech of the application of branch stent graft in the endovascular treatment of aortic arch dissection, to compare four ways that reconstruct the aortic arch. Professor Lu said, the hybrid surgery changes the morphology of the aortic arch and leads to large trauma. Its mid-term outcome is satisfactory but its long-term result remains uncertain and needs to be followed-up. In-situ fenestrated technique may result in brain ischemia and type III endoleak, and meanwhile due to the randomness of fenestration, its mid-term result is unknown. The chimney technique could lead to "gutter" endoleak due to the gutter between the branch stent graft and the main body. He pointed out, Castor™ is the most promising technology platform to realize endovascular reconstruction of aortic arch as it adopts unibody design that results in precise positioning and reduced type III endoleak.

Professor Hongkun Zhang of the First Affiliated Hospital of Zhejiang University, Professor Tong Qiao of Nanjing Drum Tower Hospital, and Professor Wei Li of People's Hospital of Peking University respectively delivered speeches regarding the application of in-situ fenestrated technique in the treatment of aortic arch disease, treatment of the aortic dissection, IMH and PAU, as well as the management of LSA in TEVAR, which was well received by experts in attendance.

Castor™ is the world's first branched stent graft system designed for an entirely endovascular treatment of thoracic dissection encroaching the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery. Castor™ employs an easy-to-use unibody design, including a main body and a branch stent graft for the left subclavian artery as a whole. In 2015, Castor™ was granted the Green-Path by the China Food and Drug Administration ("CFDA"), a special fast-track procedure for innovative medical devices to gain CFDA approval, and is expected to gain the CFDA approval within this year to officially enter the China market.